A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis.
BACKGROUND
The issue of when to start treatment in Parkinson's disease (PD) remains controversial. Some favour treatment at diagnosis while others opt for a "wait and watch" policy. The effect of the latter policy on the self reported health status of people with PD is unknown.


OBJECTIVE
To record self reported health status through longitudinal use of a validated PD specific questionnaire (PDQ-39) in untreated PD patients in multiple centres in the UK. To compare patients who were left untreated with those who were offered treatment during follow-up.


METHODS
A multicentre, prospective, "real life" observational audit based study addressing patient reported outcomes in relation to self reported health status and other sociodemographic details.


RESULTS
198 untreated PD were assessed over a mean period of 18 months. During two follow-up assessments, the self reported health status scores in all eight domains of the PDQ-39 and the overall PDQ-39 summary index worsened significantly (p<0.01) in patients left untreated. In a comparative group in whom treatment was initiated at or soon after diagnosis, there was a trend towards improvement in self reported health status scores after treatment was started.


CONCLUSIONS
This study addresses for the first time self reported health status, an indicator of health related quality of life, in untreated PD. The findings may strengthen the call for re-evaluation of the policy to delay treatment in newly diagnosed patients with PD.
Grosset
D
D
Institute of Neurological Sciences, Glasgow, UK.
Taurah
L
L
Burn
D J
DJ
MacMahon
D
D
Forbes
A
A
Turner
K
K
Bowron
A
A
Walker
R
R
Findley
L
L
Foster
O
O
Patel
K
K
Clough
C
C
Castleton
B
B
Smith
S
S
Carey
G
G
Murphy
T
T
Hill
J
J
Brechany
U
U
McGee
P
P
Reading
S
S
Brand
G
G
Kelly
L
L
Breen
K
K
Ford
S
S
Baker
M
M
Williams
A
A
Hearne
J
J
Qizilbash
N
N
Chaudhuri
K Ray
KR
D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D006304:Health Status; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D010347:Patient Care Planning; D011379:Prognosis; D011788:Quality of Life
D000978:Antiparkinson Agents